RGBP — Regen BioPharma Inc

OTC · Health Care · Pharmaceuticals · CIK 1589150 ·
Last close
$0.00
Market Cap
$153.6K
52W High
$0.00
52W Low
$0.00
ADV30
15,130,061
Next earnings
Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. The company engages in identifying small molecules that inhibit or express NR2F6, leading to immune cell activation for oncology applications and immune cell suppression for autoimmune diseases. It also develops several products: HemaXellarate, a cellular therapeutic product derived from autologous stromal vascular fraction from adipose tissue; dCellVax, an autologous dendritic cell treated with an siRNA inhibitor of indoleamine-2,3-dioxygenase; tCellVax, which is treated with siRNA to inhibit NR2F6, with the cells re-infused into the patient; DiffronC, which uses proprietary siRNA in vivo to inhibit cancer growth and activate T cells; and DuraCAR, comprising CAR-T cells treated with an shRNA targeting the gene NR2F6. Regen BioPharma was incorporated in 2012 and is based in La Mesa, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 59,065 -153,709 991,927 260,194 271 5,619,062
Dec 2025 59,065 -551,624 -967,853 237,076 4,578 6,810,073
Sep 2025 59,366 -123,055 -572,469 274,628 69,555 6,555,811
Jun 2025 59,065 -40,756 -167,292 196,841 1,761 6,012,532

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-515,153
Investing CF
Financing CF
$519,595
CapEx
Dividends Paid
Buybacks
EPS Diluted TTM
$-0.15
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-22,659,473
Inventory
Receivables
$232,298
ST Investments
EBIT TTM
$-1,519,122
Pretax Income TTM
$-1,726,968
Interest Exp TTM
$207,846
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$236,560
EBITDA
Free Cash Flow
$-436,287
Enterprise Value
$1,153,542
Total Cash
$271
Total Debt
$959,146
Shares Out
511,957,643
Trailing EPS
$-0.02
Book Value
$-0.01
ROE
ROA
-252.9%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Sep 2025 236,561 -338,540 -1,274,502 274,628 6,555,811 -383,591
Sep 2024 236,560 -417,221 -668,255 161,084 5,378,456 -751,536
Sep 2023 236,560 -686,949 1,023,508 353,617 5,457,616 -173,917
Sep 2022 235,517 -339,605 2,227,034 559,002 8,595,061 -606,921

Peers — same industry

TickerNameMarket CapLastDaily %
GCAN Greater Cannabis Company, Inc. $137.0K $0.14
BDPT BIOADAPTIVES, INC. $132.1K $0.01
BNIGF Beroni Group Ltd $180.0K $0.01
ADTX Aditxt, Inc. $129.8K $0.25
IOBTQ IO Biotech, Inc. $215.8K $0.00

News headlines (Yahoo Finance, 1h cache)

Presenting on Emerging Growth Conference 90 Day 1 on February 25; Register to live stream
2026-02-24 12:00 · Yahoo
Presenting on Emerging Growth Conference 89 Day 1 on January 21; Register to live stream
2026-01-20 12:00 · Yahoo
Presenting on Emerging Growth Conference 88 Day 1 on December 10; Register to live stream
2025-12-09 12:00 · Yahoo
Goldman Small Cap Research Publishes New Research Report on Regen BioPharma, Inc.
2025-11-05 14:40 · Yahoo
Presenting on Emerging Growth Conference 87 Day 2 on October 23; Register to live stream
2025-10-22 11:00 · Yahoo
Regen BioPharma Update on Orphan Drug Application for HemaXellerate Will Be Presented At Emerging Growth Conference on September 24, 2025
2025-09-23 12:00 · Yahoo
Presenting on Emerging Growth Conference 86 Day 1 on September 24; Register to live stream
2025-09-23 11:00 · Yahoo
Regen BioPharma Prepares Response For FDA Regarding Its Orphan Drug Application for HemaXellerate
2025-09-16 12:00 · Yahoo
Regen BioPharma Explores Expanded Use of HemaXellerate for Chemotherapy-Induced Bone Marrow Suppression
2025-09-04 12:00 · Yahoo
Presenting on Emerging Growth Conference 85 Day 1 on August 20; Register to live stream
2025-08-19 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.